| Recruiting | Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surg Hemophilia A | Phase 4 | 2026-04-01 |
| Not Yet Recruiting | Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions | Phase 3 | 2025-12-01 |
| Recruiting | Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Indu Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk | — | 2025-02-14 |
| Recruiting | Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Acquired Antithrombin Deficiency | Phase 3 | 2024-08-21 |
| Recruiting | Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficien Acute Hereditary Angio Edema | Phase 3 | 2024-04-30 |
| Recruiting | Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study Severe Hemophilia A | Phase 4 | 2023-11-28 |
| Recruiting | Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Dem Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | 2023-10-01 |
| Completed | Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardi Bleeding Cardiac Surgery Patients | Phase 3 | 2022-11-30 |
| Recruiting | Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Congenital Antithrombin Deficiency | Phase 3 | 2022-07-01 |
| Completed | Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Von Willebrand Disease | Phase 3 | 2021-09-22 |
| Recruiting | Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor Acute Major Bleeding | Phase 3 | 2021-09-01 |
| Active Not Recruiting | Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobuli Primary Immune Deficiency | Phase 3 | 2021-08-04 |
| Completed | Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neurops Pediatric Acute-Onset Neuropsychiatric Syndrome | Phase 3 | 2021-06-30 |
| Terminated | Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency Congenital Fibrinogen Deficiency | — | 2021-01-28 |
| Completed | Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treat Covid19 | — | 2020-10-19 |
| Completed | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Pa Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | 2020-10-05 |
| Completed | Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patie Von Willebrand Diseases | Phase 3 | 2020-06-18 |
| Completed | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression Covid-19 | Phase 3 | 2020-06-01 |
| Terminated | Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopeni Chronic Immune Thrombocytopenia | Phase 4 | 2020-01-21 |
| Active Not Recruiting | Effectiveness and Tolerability of Eqwilate in Real-life Conditions VWD - Von Willebrand's Disease | — | 2019-11-27 |
| Completed | Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With P Primary Immune Deficiency Disorder | Phase 3 | 2019-10-17 |
| Terminated | Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A Severe Hemophilia A | Phase 1 / Phase 2 | 2019-07-03 |
| Completed | Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment Von Willebrand Diseases | — | 2019-06-25 |
| Completed | Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data Bleeding | — | 2019-02-21 |
| Terminated | Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis Dermatomyositis | Phase 3 | 2018-08-02 |
| Withdrawn | Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjec Alpha 1-Antitrypsin Deficiency | Phase 2 | 2018-07-01 |
| Terminated | Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq Hemophilia A | — | 2018-06-28 |
| Completed | Observational Study of the Use of octaplasLG®. Thrombotic Thrombocytopenic Purpura | — | 2018-03-02 |
| Recruiting | Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemo Haemophilia A | — | 2018-02-13 |
| Completed | Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients Wit Severe Hemophilia A | Phase 3 | 2017-11-22 |
| Completed | Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Emergency Care for Severe Bleeding While on Anticoagulants | N/A | 2017-10-13 |
| Completed | Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammato Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy | Phase 3 | 2017-09-27 |
| Completed | The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of P Secondary Immune Deficiency | — | 2017-09-25 |
| Completed | Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Significant Bleeding Risk | Phase 3 | 2017-06-08 |
| Terminated | Octaplas Adult TTP Trial Thrombotic Thrombocytopenic Purpura | — | 2017-06-06 |
| Completed | Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Primary Immune Deficiency Disorder | Phase 3 | 2017-03-07 |
| Completed | Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Dermatomyositis | Phase 3 | 2017-02-27 |
| Completed | Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A Severe Hemophilia A | Phase 3 | 2016-12-01 |
| Terminated | Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases Autoimmune Diseases | — | 2016-11-23 |
| Completed | CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN Primary Immunodeficiency | Phase 3 | 2016-03-01 |
| Completed | Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Congenital Fibrinogen Deficiency | Phase 3 | 2015-12-01 |
| Terminated | Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation Coagulopathy, Endstage Liver Disease | — | 2015-08-01 |
| Completed | A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutane Primary Immunodeficiency | Phase 4 | 2015-07-29 |
| Completed | Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophili Severe Haemophilia A | Phase 3 | 2015-05-01 |
| Completed | Octaplas Pediatric Plasma Exchange Trial Adverse Effects in the Therapeutic Use of Plasma Substitutes | Phase 4 | 2015-04-01 |
| Completed | Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ Hemophilia A | — | 2015-01-01 |
| Completed | Octaplas Pediatric Plasma Replacement Trial Liver Surgery, Liver Dysfunction, Coagulopathy | Phase 4 | 2014-12-01 |
| Completed | Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding Duri Congenital Fibrinogen Deficiency | Phase 3 | 2014-09-01 |
| Completed | Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII Severe Hemophilia A | Phase 3 | 2014-04-01 |
| Completed | Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps Primary Immunodeficiency (PID) | Phase 4 | 2014-04-01 |
| Completed | Study of Octanorm Subcutaneous IG in Patients With PID Primary Immune Deficiency Disorder | Phase 3 | 2014-03-01 |
| Completed | Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Sev Severe Haemophilia A | Phase 3 | 2013-08-01 |
| Completed | Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap Congenital Fibrinogen Deficiency, Afibrinogenemia | Phase 2 | 2013-06-01 |
| Completed | Octagam 5% Versus Comparator Post Marketing Trial Primary Immune Deficiency Disorder | — | 2013-05-21 |
| Completed | Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients Severe Hemophilia A | Phase 3 | 2013-02-01 |
| Completed | Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease Von Willebrand Disease | — | 2012-10-01 |
| Terminated | Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 / Phase 3 | 2011-10-01 |
| Completed | Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia Primary Thrombocytopenia | Phase 3 | 2011-10-01 |
| Completed | Non-Interventional Study on the Tolerability and Efficacy of IVIG Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG | — | 2011-08-01 |
| Completed | Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery Prevent Bleeding in Major Surgery | Phase 3 | 2011-06-01 |
| Completed | Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTP Severe Hemophilia A | Phase 3 | 2011-06-01 |
| Completed | High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam) Primary Immunodeficiency Disease | Phase 3 | 2011-05-01 |
| Completed | Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A Severe Hemophilia A | Phase 3 | 2010-06-01 |
| Completed | Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII Hemophilia A | Phase 2 | 2010-05-01 |
| Completed | A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases Primary Immunodeficiency Diseases | Phase 3 | 2010-01-01 |
| Completed | A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD Comparison of Octaplas LG and Octaplas SD | Phase 1 | 2009-12-01 |
| Completed | Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Dise Alzheimer's Disease | Phase 2 | 2009-02-01 |
| Terminated | Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases Immunologic Deficiency Syndromes | Phase 3 | 2009-01-01 |
| Completed | Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Reversal of Anticoagulant Treatment | Phase 3 | 2008-05-01 |
| Terminated | Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpur Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | 2007-05-01 |
| Completed | Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Ad Immune Thrombocytopenic Purpura | Phase 3 | 2006-06-01 |